

PETER A. SEUBERT ET AL.
Application No.: 08/466,554
Page 2

PATENT

REMARKS

I. STATUS OF THE CLAIMS

Claims 42-50 were pending. Applicants have canceled claim 49 without prejudice. Therefore, claims 42-48 and 50 are presented for examination.

Applicants have canceled claim 49 in order to expedite prosecution. Applicants maintain their position that the specification includes written support for the canceled claim.

Applicants also request entry of the amendments in the paper submitted August 7, 1997.

CONCLUSION

In view of the foregoing, Applicants believe all claims now pending in this application are in condition for allowance. The issuance of a formal Notice of Allowance at an early date is respectfully requested.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at (415) 576-0200.

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, CA 94111-3834

ph: (415) 576-0200
fax: (415) 576-0300

j:\athena\2120\2120.am2

Respectfully submitted,


John Storella
Reg. No. 32,944

PETER A. SEUBERT ET AL.
Application No.: 08/466,554
Page 3

PATENT

APPENDIX 1 – PENDING CLAIMS

42. (Previously twice amended) A method for screening a compound to determine its ability to alter the amount of an $A\beta(x- \geq 41)$ peptide in a fluid sample comprising:

measuring a first amount of one or more soluble $A\beta(x- \geq 41)$ peptides in the fluid sample of a non-human animal model that exhibits cerebral deposition of $A\beta$;

administering the compound to the non-human animal model;

measuring a second amount of said one or more soluble $A\beta(x- \geq 41)$ peptides in the fluid sample of the non-human animal model; and

comparing the first amount with the second amount,

the difference indicating whether the compound increases, decreases, or leaves unchanged the amount of soluble $A\beta(x- \geq 41)$ in the fluid sample.

43. (Previously once amended) The method of claim 42 wherein the non-human animal model is a rodent model.

44. (Previously once amended) The method of claim 43 wherein the rodent model is a mouse model.

45. (Previously once amended) The method of claim 42 wherein the non-human animal model is a transgenic animal model having an expression cassette that drives expression of a sequence which encodes the Swedish mutation of an APP gene.

46. (Previously once amended) The method of claim 45 wherein the non-human animal model is a rodent model.

47. (Previously once amended) The method of claim 46 wherein the rodent model is a mouse model.

48. (As filed) The method of claim 42 wherein $A\beta(x- \geq 41)$ is $A\beta(x-42)$.

PETER A. SEUBERT ET AL.
Application No.: 08/466,554
Page 4

PATENT

50. (New) The method of claim 42 wherein the fluid sample is cerebrospinal fluid.

VI. AMENDMENT

versi October 1, 1997

Docket No.: 15270-002120Date Due: Send today!A. REPORTING OFFICE ACTION

Reporting letter
 Copy of Office Action
 cc's

B. AMENDMENT OR PRELIMINARY AMENDMENT

Postcard
 Transmittal letter (in triplicate) ✓
 Check or authorization to charge account
 Petition for Extension of Time: ____ mo. (in triplicate)
 Fee or authorization to charge account
 Amendment (Response) ✓
 Exhibits:
 Response to Restriction Requirement
 No fee -- Send to: **Box Non-Fee Amendment**
 Final: § 1.116
 Consider Notice of Appeal! (Below)
 Send to: **Box AF**
 Expedited if within 2 months
 Petition under § 1.129 to withdraw final communication
 Decl under § 1.131 of: _____
 Exhibits:
 Decl under § 1.132 of: _____
 Exhibits:
 Associate Power of Attorney
 Terminal Disclaimer
 Certificate under Rule 3.73(b)
 Petition under Rule 48 to delete inventors
 Other _____
 Exhibits:
 Do you need an IDS?
 Certificate of Mailing
 Certificate of Fax ✓
 File a continuation while case is still alive?

C. NOTICE OF APPEAL

Notice of Appeal
 Cite rejected claims to be appealed
 Fee or authorization to charge account

D. REPORTING RESPONSE

Reporting letter
 Copy of response
 cc's

ENTITY:

Large
 Small